L Schimmöller1, M Quentin2, D Blondin1, F Dietzel1, A Hiester3, C Schleich1, C Thomas1, R Rabenalt3, H E Gabbert4, P Albers3, G Antoch1, C Arsov3. 1. Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, Moorenstr. 5, D-40225, Dusseldorf, Germany. 2. Medical Faculty, Department of Diagnostic and Interventional Radiology, University Dusseldorf, Moorenstr. 5, D-40225, Dusseldorf, Germany. Michael.Quentin@med.uni-duesseldorf.de. 3. Medical Faculty, Department of Urology, University Dusseldorf, Moorenstr. 5, D-40225, Dusseldorf, Germany. 4. Medical Faculty, Department of Pathology, University Dusseldorf, Moorenstr. 5, D-40225, Dusseldorf, Germany.
Abstract
PURPOSE: This study evaluates the feasibility of performing less than two core biopsies per MRI-lesion when performing targeted MR-guided in-bore prostate biopsy. METHODS: Retrospectively evaluated were 1545 biopsy cores of 774 intraprostatic lesions (two cores per lesion) in 290 patients (66 ± 7.8 years; median PSA 8.2 ng/ml) regarding prostate cancer (PCa) detection, Gleason score, and tumor infiltration of the first (FBC) compared to the second biopsy core (SBC). Biopsies were acquired under in-bore MR-guidance. RESULTS: For the biopsy cores, 491 were PCa positive, 239 of 774 (31 %) were FBC and 252 of 771 (33 %) were SBC (p = 0.4). Patient PCa detection rate based on the FBC vs. SBC were 46 % vs. 48 % (p = 0.6). For clinically significant PCa (Gleason score ≥4 + 3 = 7) the detection rate was 18 % for both, FBC and SBC (p = 0.9). Six hundred and eighty-seven SBC (89 %) showed no histologic difference. On the lesion level, 40 SBC detected PCa with negative FBC (7.5 %). Twenty SBC showed a Gleason upgrade from 3 + 3 = 6 to ≥3 + 4 = 7 (2.6 %) and 4 to ≥4 + 3 = 7 (0.5 %). CONCLUSION: The benefit of a second targeted biopsy core per suspicious MRI-lesion is likely minor, especially regarding PCa detection rate and significant Gleason upgrading. Therefore, a further reduction of biopsy cores is reasonable when performing a targeted MR-guided in-bore prostate biopsy. KEY POINTS: • Higher PI-RADS overall score (IV-V) correlated well with PCa detection rate • In more than 80 % SBC was concordant regarding overall PCa detection • In almost 90 % there was no Gleason upgrading by the SBC • Only 2/54 (3.7 %) csPCa was missed when the SBC was omitted • For IB-GB a further reduction of biopsy cores is reasonable.
PURPOSE: This study evaluates the feasibility of performing less than two core biopsies per MRI-lesion when performing targeted MR-guided in-bore prostate biopsy. METHODS: Retrospectively evaluated were 1545 biopsy cores of 774 intraprostatic lesions (two cores per lesion) in 290 patients (66 ± 7.8 years; median PSA 8.2 ng/ml) regarding prostate cancer (PCa) detection, Gleason score, and tumor infiltration of the first (FBC) compared to the second biopsy core (SBC). Biopsies were acquired under in-bore MR-guidance. RESULTS: For the biopsy cores, 491 were PCa positive, 239 of 774 (31 %) were FBC and 252 of 771 (33 %) were SBC (p = 0.4). Patient PCa detection rate based on the FBC vs. SBC were 46 % vs. 48 % (p = 0.6). For clinically significant PCa (Gleason score ≥4 + 3 = 7) the detection rate was 18 % for both, FBC and SBC (p = 0.9). Six hundred and eighty-seven SBC (89 %) showed no histologic difference. On the lesion level, 40 SBC detected PCa with negative FBC (7.5 %). Twenty SBC showed a Gleason upgrade from 3 + 3 = 6 to ≥3 + 4 = 7 (2.6 %) and 4 to ≥4 + 3 = 7 (0.5 %). CONCLUSION: The benefit of a second targeted biopsy core per suspicious MRI-lesion is likely minor, especially regarding PCa detection rate and significant Gleason upgrading. Therefore, a further reduction of biopsy cores is reasonable when performing a targeted MR-guided in-bore prostate biopsy. KEY POINTS: • Higher PI-RADS overall score (IV-V) correlated well with PCa detection rate • In more than 80 % SBC was concordant regarding overall PCa detection • In almost 90 % there was no Gleason upgrading by the SBC • Only 2/54 (3.7 %) csPCa was missed when the SBC was omitted • For IB-GB a further reduction of biopsy cores is reasonable.
Authors: M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: JAMA Date: 2015-01-27 Impact factor: 56.272
Authors: Michael Quentin; Dirk Blondin; Christian Arsov; Lars Schimmöller; Andreas Hiester; Erhard Godehardt; Peter Albers; Gerald Antoch; Robert Rabenalt Journal: J Urol Date: 2014-05-24 Impact factor: 7.450
Authors: Vincenzo Scattoni; Carmen Maccagnano; Umberto Capitanio; Andrea Gallina; Alberto Briganti; Francesco Montorsi Journal: World J Urol Date: 2014-06-08 Impact factor: 4.226
Authors: Christian Arsov; Robert Rabenalt; Dirk Blondin; Michael Quentin; Andreas Hiester; Erhard Godehardt; Helmut E Gabbert; Nikolaus Becker; Gerald Antoch; Peter Albers; Lars Schimmöller Journal: Eur Urol Date: 2015-06-23 Impact factor: 20.096
Authors: Jörg Simon; Rainer Kuefer; Georg Bartsch; Björn G Volkmer; Richard E Hautmann; Hans-Werner Gottfried Journal: BJU Int Date: 2008-03-05 Impact factor: 5.588
Authors: Andriy Fedorov; Kemal Tuncali; Lawrence P Panych; Janice Fairhurst; Elmira Hassanzadeh; Ravi T Seethamraju; Clare M Tempany; Stephan E Maier Journal: Magn Reson Imaging Date: 2016-05-27 Impact factor: 2.546
Authors: Sadhna Verma; Peter L Choyke; Steven C Eberhardt; Aytekin Oto; Clare M Tempany; Baris Turkbey; Andrew B Rosenkrantz Journal: Radiology Date: 2017-11 Impact factor: 11.105
Authors: M Quentin; C Arsov; T Ullrich; B Valentin; A Hiester; D Blondin; P Albers; G Antoch; L Schimmöller Journal: Eur Radiol Date: 2019-06-27 Impact factor: 5.315
Authors: Susanne Tewes; Inga Peters; Ansgar Tiemeyer; Matti Peperhove; Dagmar Hartung; Stefanie Pertschy; Markus A Kuczyk; Frank Wacker; Katja Hueper Journal: Biomed Res Int Date: 2017-09-28 Impact factor: 3.411